Acerus Pharmaceuticals (TRLPF) versus Puma Biotechnology (PBYI) Head-To-Head Review

Share on StockTwits

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Puma Biotechnology’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acerus Pharmaceuticals $7.38 million 2.87 -$18.79 million N/A N/A
Puma Biotechnology $251.00 million 6.02 -$113.60 million ($2.99) -13.13

Acerus Pharmaceuticals has higher earnings, but lower revenue than Puma Biotechnology.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Acerus Pharmaceuticals and Puma Biotechnology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acerus Pharmaceuticals 0 0 0 0 N/A
Puma Biotechnology 3 5 4 0 2.08

Puma Biotechnology has a consensus price target of $52.20, indicating a potential upside of 32.93%. Given Puma Biotechnology’s higher possible upside, analysts plainly believe Puma Biotechnology is more favorable than Acerus Pharmaceuticals.

Institutional & Insider Ownership

0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of Puma Biotechnology shares are held by institutional investors. 21.5% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Acerus Pharmaceuticals and Puma Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acerus Pharmaceuticals -254.66% -221.27% -84.68%
Puma Biotechnology -45.22% -258.02% -51.18%

Volatility & Risk

Acerus Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.


Puma Biotechnology beats Acerus Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

About Puma Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with's FREE daily email newsletter.